GLP-1 nanomedicine alleviates gut inflammation.
Nanomedicine
; 13(2): 659-665, 2017 02.
Article
in En
| MEDLINE
| ID: mdl-27553076
ABSTRACT
The gut hormone, glucagon like peptide-1 (GLP-1) exerts anti-inflammatory effects. However, its clinical use is limited by its short half-life. Previously, we have shown that GLP-1 as a nanomedicine (GLP-1 in sterically stabilized phospholipid micelles, GLP-1-SSM) has increased in vivo stability. The current study was aimed at testing the efficacy of this GLP-1 nanomedicine in alleviating colonic inflammation and associated diarrhea in dextran sodium sulfate (DSS) induced mouse colitis model. Our results show that GLP-1-SSM treatment markedly alleviated the colitis phenotype by reducing the expression of pro-inflammatory cytokine IL-1ß, increasing goblet cells and preserving intestinal epithelial architecture in colitis model. Further, GLP-1-SSM alleviated diarrhea (as assessed by luminal fluid) by increasing protein expression of intestinal chloride transporter DRA (down regulated in adenoma). Our results indicate that GLP-1 nanomedicine may act as a novel therapeutic tool in alleviating gut inflammation and associated diarrhea in inflammatory bowel disease (IBD).
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Colitis
/
Glucagon-Like Peptide 1
/
Nanomedicine
/
Inflammation
Type of study:
Etiology_studies
Limits:
Animals
Language:
En
Journal:
Nanomedicine
Journal subject:
BIOTECNOLOGIA
Year:
2017
Document type:
Article
Affiliation country:
Estados Unidos
Publication country:
EEUU
/
ESTADOS UNIDOS
/
ESTADOS UNIDOS DA AMERICA
/
EUA
/
UNITED STATES
/
UNITED STATES OF AMERICA
/
US
/
USA